Heparin / Taurolidine Catheter Lock Solution Side Effects

Applies to heparin/taurolidine catheter lock solution: intraluminal solution.

General adverse events

The most common adverse effects occurring in 2% of patients or greater included hemodialysis catheter malfunction, hemorrhage/bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia.^[Ref]

Gastrointestinal

• Common (1% to 10%): Nausea/procedural nausea, vomiting/procedural vomiting

Hematologic

• Common (1% to 10%): Hemorrhage/bleeding, thrombocytopenia
• Uncommon (0.1% to 1%): Heparin-induced thrombocytopenia

Hemorrhage/bleeding includes hematoma/hemorrhage, intracranial hemorrhage, arteriovenous graft or fistula site hemorrhage, catheter site hematoma/hemorrhage, cerebral/cerebellar hemorrhage, eye/conjunctival hemorrhage, gastrointestinal hemorrhage, hematuria, hemobilia, hemoptysis, renal hematoma, and vaginal/uterine hemorrhage.

Hypersensitivity

• Uncommon (0.1% to 1%): Drug hypersensitivity

Metabolic

• Frequency not reported: Hypocalcemia

Musculoskeletal

• Common (1% to 10%): Musculoskeletal (non-cardiac) chest pain or discomfort

Nervous system

• Common (1% to 10%): Dizziness
• Frequency not reported: Dysgeusia
• Postmarketing reports: Paresthesia

Other

• Very common (10% or more): Hemodialysis catheter/device malfunction (17%), use of thrombolytic agent (16%), catheter removal (12%)
• Common (1% to 10%): Catheter removal without thrombolytic agent use

See also:

Further information

Heparin/taurolidine catheter lock solution side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer